Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Metabolic Disorders

Set Alert for Metabolic Disorders

PBM Formulary Exclusions On The Rise, PhRMA Says

According to a report commissioned by PhRMA, the three largest pharmacy benefit managers continue to exclude more drugs from standard formularies, including those with expedited FDA approval. 

Reimbursement Market Access

Lilly’s Mounjaro Diabetes Approval Is First Challenge To Novo’s GLP-1 Franchise

The GLP-1/GIP agonist tirzepatide is a key addition to Lilly’s commercial portfolio as the company leans on new products to deliver on volume-driven growth through the current decade. 

Approvals Launches

Deerfield And Illumina Join Forces To Fund New Discoveries, New Companies

Investor Deerfield Management and genomic sequencing giant Illumina entered into a five-year partnership to identify novel targets and drug candidates that may be spun out into new companies.

Deals Innovation

Vertex Diabetes Cell Therapy Trial On Hold – As First Patient Free From Insulin Injections

Vertex expresses surprise at the US FDA’s call for a halt, as it reveals an exciting milestone reached - the first trial participant now producing their own insulin.

Clinical Trials Commercial

Novo’s Wegovy Excels But Lilly Rival Hot On Heels

After months of manufacturing blunders, the Danish major’s obesity drug has shown its blockbuster potential in the first quarter but rival Eli Lilly could soon stoke up the competition.

Sales & Earnings Companies

Tirzepatide’s Glowing Obesity Data Steal Show On Lilly’s Earnings Call

Tirzepatide shows ability to produce a mean 52-pound weight loss at 72 weeks, setting up a market showdown with Novo’s Wegovy. Lilly’s quarterly call included reassurance about donanemab for Alzheimer’s and high growth for its COVID-19 antibody.

Sales & Earnings Business Strategies

Boehringer Pharma Chief Confident Of Continued Success For Jardiance

Carinne Brouillon, head of the German major’s human pharma business unit, tells Scrip that Jardiance’s leadership in interconnected cardio-metabolic-renal diseases has been demonstrated and the product is set to keep rising as new indications come onboard.

Business Strategies Leadership

Novo Nordisk Has A Plan To Get Wegovy Launch Back On The Rails

The company is targeting revenues of DKK25bn ($3.66bn) from Wegovy for obesity in 2025, with plans to amp up the US launch this year following an initial supply disruption.

Metabolic Disorders Launches

Civica Takes On The Challenge Of Insulin Affordability

The non-profit organization plans to make biosimilar versions of Lantus, Humalog and Novolog and sell them for no more than $30/vial.

Biosimilars Pricing Strategies

Bugs As Drugs: The Budding Microbiome Modulator Pipeline

INFOGRAPHIC: The sheer number of micro-organisms in the human body and their functions makes the microbiome a ripe target for therapeutic intervention. While still rather early, data show the microbiome modulator pipeline has immense potential across a range of therapeutic areas, not just in gastrointestinal disease.

Infectious Diseases Companies

Daewoong's SGLT-2 Inhibitor Set For First Filing After Phase III

Korean pharma firm poised to file for domestic approval of SGLT-2 inhibitor enavogliflozin after positive top-line Phase III data, marking progress for the country's first drug in the already crowded class. But will it be competitive?

South Korea Clinical Trials

Novo Nordisk’s Diabetes Franchise Bears The Weight Of Disappointing Obesity Sales

The Danish firm’s GLP-1 drugs are behind much of its 2021 sales success as ongoing problems with the manufacturing of in-demand obesity product Wegovy dampen growth.

Sales & Earnings Companies
See All
UsernamePublicRestriction

Register